Cooley, Latham Handle $686M AMAG-Allos Merger

Law360, New York (July 20, 2011, 3:17 PM EDT) -- Drug developers AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. announced Wednesday an all-stock merger valued at about $686 million that is expected to strengthen their product lines and streamline their costs.

Massachusetts-based AMAG and Colorado-based Allos said that by combining, they'll save between $55 million and $60 million, most of which will be realized in the first fiscal year after the merger closes.

"We are very excited about this merger as it creates a combined company with an enhanced commercial presence in attractive market segments supported...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.